PROSTIN E2 Rx
Generic Name and Formulations:
Dinoprostone 20mg; per vaginal suppository.
Indications for PROSTIN E2:
For the termination of pregnancy from the 12th through the 20th gestational weeks. For the evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age. Management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole).
Insert one supp high into vagina. Remain in supine position for 10mins following insertion. May insert subsequent supp at 3–5hr intervals until abortion occurs. Continuous administration for more than 2 days is not recommended.
Acute pelvic inflammatory disease. Active cardiac, pulmonary, renal or hepatic disease.
Only use with strict adherence to recommended dosages. Should only be used by medically trained personnel in a hospital setting.
Not indicated if fetus in utero has reached the stage of viability. Not for use in cervical ripening or other indication in patients with term pregnancy. Asthma. Hypo-or hypertension. Anemia. Jaundice. Diabetes. Epilepsy. History of cardiac, renal, or hepatic disease. Cervicitis. Infected endocervical lesions. Acute vaginitis. Compromised (scarred) uteri. Remove supp if hypersensitivity reaction is suspected. Pregnancy.
Concomitant other oxytocic agents: not recommended.
Vomiting, transient pyrexia (see full labeling re: PGEs induced pyrexia vs. endometritis pyrexia), diarrhea, nausea, headache, chills, transient decrease in BP; MI in patients with history of CVD, hypersensitivity.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally